Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Ultragenyx Pharmaceutical missed estimated earnings by 33.58%, reporting an EPS of $-1.79 versus an estimate of $-1.34.
Revenue was up $8.15 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.33, which was followed by a 1.38% increase in the share price the next day.
Here's a look at Ultragenyx Pharmaceutical's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -1.41 | -1.36 | -1.24 | -1.16 |
| EPS Actual | -1.08 | -1.81 | -2.03 | -0.37 |
| Revenue Estimate | 81.55M | 85.03M | 77.04M | 70.54M |
| Revenue Actual | 81.65M | 86.97M | 99.39M | 91.54M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
